Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

39.42 -0.18 (-0.44%)
Streaming Delayed Price Updated: 11:56 AM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gsk Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January
Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on... 
Via Benzinga
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. 
Via Benzinga
3 Growth at a Reasonable Price (GARP) Stocks for Balanced Growth
GARP stocks are less likely to plunge than growth stocks with high valuations and more likely to generate strong growth than value stocks. 
Via InvestorPlace
Merck's Chronic Cough Treatment Candidate Receives Second Time FDA Rejection
The FDA issued a Complete Response Letter (CRL) regarding Merck & Co Inc's (NYSE: MRK) New Drug Application (NDA) for gefapixant under development for the treatment of refractory chronic cough (RCC) or... 
Via Benzinga
Exposures Product Safety
GSK's Jemperli Cancer Drug Hits Primary Goal In Endometrial Cancer Study
GSK plc (NYSE: GSK)  
Via Benzinga
Looking Into GSK's Recent Short Interest
Via Benzinga
Price Over Earnings Overview: GSK
Via Benzinga
Looking Into GSK's Recent Short Interest
Via Benzinga
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n 
Via Benzinga
Exposures COVID-19
Why Is Genetic Medicines-Focused Wave Life Sciences Stock Trading Lower Today?
Wave Life Sciences Ltd (NASDAQ: WVE) has priced its previously announced underwritten public offering of 20 million shares at $5.00 per share with approximately  
Via Benzinga
Competition and Optimism: GSK's CEO Walmsley Foresees Growth Despite Competition In RSV Vaccine Market
Emma Walmsley, the Chief Executive Officer of GSK plc (NYSE: GSK), expressed confidence in its respiratory syncytial virus (RSV) vaccine, Arexvy, anticipating sales to surpass £1 billio 
Via Benzinga
3 Stocks to Sell for Tax Losses Before the New Year
While no one wants to lose in the market, you can be productive with the red ink through stocks to sell for tax losses. 
Via InvestorPlace
3 Great Foreign Companies to Invest in Right Now
The world is a big place, and many great companies are based outside our U.S. borders. 
Via The Motley Fool
GSK Frames A Comeback For Its Multiple Myeloma Drug Following Encouraging Phase 3 Data
GSK plc (NYSE: GSK) announced headline  
Via Benzinga
Merck's Latest Drug For Chronic Cough Faces FDA Pushback
A panel of advisors to the Food and Drug Administration (FDA) reportedly expressed concerns about the efficacy of Merck & Company, Inc.'s (NYSE: 
Via Benzinga
Exposures Product Safety
Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion
Sen. Tommy Tuberville bought 3 tranches of put options to sell Tesla shares at $190 a day ahead of Q3 results that set in motion a stock slump. 
Via Benzinga
Diversifying Your Portfolio With Plant-Based Options
Investors see profit potential in the plant-based market due to rising consumer demand, ESG focus, and the growth of vegan products in various industries, including pharmaceuticals. However, market... 
Via Talk Markets
Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B
Sanofi SA (NYSE: SNY) has reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over... 
Via Benzinga
Current Analysis: GSK Plc
In the pharmaceutical industry, GSK PLC ranks as one of the largest companies by total sales. 
Via Talk Markets
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
European Drug Regulator Recommends Approval Of GSK's Bone Marrow Cancer Med
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a posi 
Via Benzinga
6 Nasdaq 100 Stocks Down 40% or More that Will Soar As Much 367%
Wall Street is forever optimistic about the future for stocks and pegs these seven Nasdaq 100 stocks as ready for supersonic growth 
Via InvestorPlace
3 Healthcare Stocks Getting Help From the Aging Population
America's aging population needs chronic conditions treatments, and these healthcare stocks are growing in the quest for healing solutions. 
Via InvestorPlace
3 Top Dividend Stock Picks for Steady Income and Capital Appreciation
Conservative investors will benefit from these top dividend stock picks that are likely to generate significant returns. 
Via InvestorPlace
Moderna Beats Sales Forecasts, But Light Guidance Could Rattle Shares
The company issued below-consensus sales views for 2023 and 2024. 
Via Investor's Business Daily
GSK Hikes Guidance On The Back Of Its Strong RSV Vaccine Launch
The company is rivaling Pfizer, which also gained approval this year for an RSV vaccine. 
Via Investor's Business Daily
GSK Lifts Annual Guidance Again Helped By Strong Launch Of RSV Vaccine, Steady Demand For Shingles Shot
GSK plc (NYSE: GSK) reported Q3 FY23 s 
Via Benzinga
Nasdaq, S&P 500 Futures Slide Ahead Of Fed Decision, Economic Data: Analyst Tells Why November Could Herald 'Good News'
U.S. stocks could start Wednesday's session lower as traders stay cautious ahead of the Fed decision and more earnings. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. 
Via Benzinga
Johnson & Johnson Offloads Rights For Hepatitis B Candidate To GSK
GSK plc (NYSE: GSK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) have  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.